These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28447476)

  • 41. The use of mutant mycobacteria as new vaccines to prevent tuberculosis.
    Hernàndez Pando R; Aguilar LD; Infante E; Cataldi A; Bigi F; Martin C; Gicquel B
    Tuberculosis (Edinb); 2006; 86(3-4):203-10. PubMed ID: 16542875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breaking Transmission with Vaccines: The Case of Tuberculosis.
    Gonzalo-Asensio J; Aguilo N; Marinova D; Martin C
    Microbiol Spectr; 2017 Jul; 5(4):. PubMed ID: 28710848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunization strategies against pulmonary tuberculosis: considerations of T cell geography.
    Horvath CN; Xing Z
    Adv Exp Med Biol; 2013; 783():267-78. PubMed ID: 23468114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meeting report: 5th Global Forum on TB Vaccines, 20-23 February 2018, New Delhi India.
    Atmakuri K; Penn-Nicholson A; Tanner R; Dockrell HM
    Tuberculosis (Edinb); 2018 Dec; 113():55-64. PubMed ID: 30514514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel approaches to tuberculosis vaccine development.
    Kaufmann SH; Weiner J; von Reyn CF
    Int J Infect Dis; 2017 Mar; 56():263-267. PubMed ID: 27816661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deciphering protective immunity against tuberculosis: implications for vaccine development.
    Counoupas C; Triccas JA; Britton WJ
    Expert Rev Vaccines; 2019 Apr; 18(4):353-364. PubMed ID: 30793629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Construction and Characterization of the Mycobacterium tuberculosis
    Hernandez-Pando R; Shin SJ; Clark S; Casonato S; Becerril-Zambrano M; Kim H; Boldrin F; Mata-Espinoza D; Provvedi R; Arbues A; Marquina-Castillo B; Cioetto Mazzabò L; Barrios-Payan J; Martin C; Cho SN; Williams A; Manganelli R
    Infect Immun; 2019 Dec; 88(1):. PubMed ID: 31591165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Towards new TB vaccines: What are the challenges?
    Dockrell HM
    Pathog Dis; 2016 Jun; 74(4):ftw016. PubMed ID: 26960944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The tuberculosis vaccine challenge.
    Brennan MJ
    Tuberculosis (Edinb); 2005; 85(1-2):7-12. PubMed ID: 15687021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protection by novel vaccine candidates, Mycobacterium tuberculosis ΔmosR and ΔechA7, against challenge with a Mycobacterium tuberculosis Beijing strain.
    Marcus SA; Steinberg H; Talaat AM
    Vaccine; 2015 Oct; 33(42):5633-5639. PubMed ID: 26363381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms of M. tuberculosis Immune Evasion as Challenges to TB Vaccine Design.
    Ernst JD
    Cell Host Microbe; 2018 Jul; 24(1):34-42. PubMed ID: 30001523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toward Tuberculosis Vaccine Development: Recommendations for Nonhuman Primate Study Design.
    Laddy DJ; Bonavia A; Hanekom WA; Kaushal D; Williams A; Roederer M; Seder RA; Sharpe S; Verreck FAW; Darrah PA
    Infect Immun; 2018 Feb; 86(2):. PubMed ID: 29203540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent mouse models and vaccine candidates for preventing chronic/latent tuberculosis infection and its reactivation.
    Pedroza-Roldán C; Flores-Valdez MA
    Pathog Dis; 2017 Aug; 75(6):. PubMed ID: 29659820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human biomarkers: can they help us to develop a new tuberculosis vaccine?
    Fletcher HA; Dockrell HM
    Future Microbiol; 2016 Jun; 11():781-7. PubMed ID: 27203133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults.
    Nicol MP; Grobler LA
    Curr Opin Mol Ther; 2010 Feb; 12(1):124-34. PubMed ID: 20140824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current perspective in tuberculosis vaccine development for high TB endemic regions.
    Husain AA; Daginawala HF; Singh L; Kashyap RS
    Tuberculosis (Edinb); 2016 May; 98():149-58. PubMed ID: 27156631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Designing tuberculosis vaccine efficacy trials - lessons from recent studies.
    Ginsberg AM
    Expert Rev Vaccines; 2019 May; 18(5):423-432. PubMed ID: 30892969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tuberculosis vaccines: hopes and hurdles.
    Ahsan MJ; Garg SK; Vashistha B; Sharma P
    Infect Disord Drug Targets; 2013 Oct; 13(5):318-21. PubMed ID: 24304353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in tuberculosis vaccine strategies.
    Skeiky YA; Sadoff JC
    Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.